ECSP056089A - Proceso para la sintesis de 3-ciano-6-alcoxi-7-nitro-4-quinolonas - Google Patents
Proceso para la sintesis de 3-ciano-6-alcoxi-7-nitro-4-quinolonasInfo
- Publication number
- ECSP056089A ECSP056089A EC2005006089A ECSP056089A ECSP056089A EC SP056089 A ECSP056089 A EC SP056089A EC 2005006089 A EC2005006089 A EC 2005006089A EC SP056089 A ECSP056089 A EC SP056089A EC SP056089 A ECSP056089 A EC SP056089A
- Authority
- EC
- Ecuador
- Prior art keywords
- cyano
- nitro
- anthranilate
- alcoxi
- ciano
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical group COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000006114 decarboxylation reaction Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- BFNYNEMRWHFIMR-UHFFFAOYSA-N tert-butyl 2-cyanoacetate Chemical compound CC(C)(C)OC(=O)CC#N BFNYNEMRWHFIMR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Se proporciona un proceso para la preparación de intermediarios de 3-ciano-6-alcoxi-7-nitro-4-quinolona útiles para la preparación de inhibidores de proteína tirosina cinasa (PTK) los cuales son útiles en el tratamiento del cáncer de la fórmula, donde R es alquilo(C1-C3) preparado mediante la reacción de un antranilato sustituido con N,N-dimetilformamida dimetilacetal para obtener una N,N-dimetilamidina la cual es condensada con t-butilcianoacetato para obtener un N-(2-ciano-2-t-butoxicarbonilvinil)antranilato, el cual es hidrolizado para producir un N-(2-ciano-2-carboxivinil)antranilato seguido por descarboxilación para obtener N-(2-ciano-2-carboxivinil)antranilato seguido por ciclización para obtener un 3-ciano-6-alcoxi-7-nitro-4-quinolona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46164703P | 2003-04-09 | 2003-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP056089A true ECSP056089A (es) | 2006-03-01 |
Family
ID=33299849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005006089A ECSP056089A (es) | 2003-04-09 | 2005-10-07 | Proceso para la sintesis de 3-ciano-6-alcoxi-7-nitro-4-quinolonas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6933388B2 (es) |
| EP (1) | EP1611103A1 (es) |
| JP (1) | JP2006522810A (es) |
| KR (1) | KR20050120788A (es) |
| CN (1) | CN100376558C (es) |
| AR (1) | AR043988A1 (es) |
| AU (1) | AU2004230864A1 (es) |
| BR (1) | BRPI0409134A (es) |
| CA (1) | CA2521294A1 (es) |
| CL (1) | CL2004000758A1 (es) |
| CO (1) | CO5640089A2 (es) |
| CR (1) | CR7991A (es) |
| EC (1) | ECSP056089A (es) |
| EG (1) | EG24122A (es) |
| MX (1) | MXPA05010685A (es) |
| NI (1) | NI200500175A (es) |
| NO (1) | NO20054375L (es) |
| RU (1) | RU2333909C2 (es) |
| TW (1) | TW200504024A (es) |
| UA (1) | UA80607C2 (es) |
| WO (1) | WO2004092138A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101723854A (zh) * | 2008-10-24 | 2010-06-09 | 上海特化医药科技有限公司 | 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体 |
| CN111116416B (zh) * | 2019-12-30 | 2021-03-23 | 中国农业大学 | 一种β-氨基丙烯腈类化合物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1207771A (en) * | 1968-03-18 | 1970-10-07 | Warner Lambert Pharmaceutical | Anti-virally active quinoline derivatives |
| EP0876345B1 (en) * | 1995-10-16 | 2004-08-18 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds as h+-atpases |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| AU6159499A (en) * | 1998-09-29 | 2000-04-17 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
-
2004
- 2004-02-04 UA UAA200510561A patent/UA80607C2/uk unknown
- 2004-04-01 TW TW093109053A patent/TW200504024A/zh unknown
- 2004-04-02 AU AU2004230864A patent/AU2004230864A1/en not_active Abandoned
- 2004-04-02 RU RU2005134653/04A patent/RU2333909C2/ru active
- 2004-04-02 MX MXPA05010685A patent/MXPA05010685A/es active IP Right Grant
- 2004-04-02 BR BRPI0409134-5A patent/BRPI0409134A/pt not_active IP Right Cessation
- 2004-04-02 WO PCT/US2004/010190 patent/WO2004092138A1/en not_active Ceased
- 2004-04-02 KR KR1020057019108A patent/KR20050120788A/ko not_active Ceased
- 2004-04-02 CA CA002521294A patent/CA2521294A1/en not_active Abandoned
- 2004-04-02 JP JP2006509628A patent/JP2006522810A/ja active Pending
- 2004-04-02 CN CNB2004800094145A patent/CN100376558C/zh not_active Expired - Fee Related
- 2004-04-02 EP EP04759094A patent/EP1611103A1/en not_active Withdrawn
- 2004-04-06 AR ARP040101163A patent/AR043988A1/es unknown
- 2004-04-07 US US10/820,115 patent/US6933388B2/en not_active Expired - Fee Related
- 2004-04-07 CL CL200400758A patent/CL2004000758A1/es unknown
-
2005
- 2005-09-14 CR CR7991A patent/CR7991A/es not_active Application Discontinuation
- 2005-09-21 NO NO20054375A patent/NO20054375L/no not_active Application Discontinuation
- 2005-10-05 CO CO05101169A patent/CO5640089A2/es not_active Application Discontinuation
- 2005-10-05 EG EGNA2005000622 patent/EG24122A/xx active
- 2005-10-07 EC EC2005006089A patent/ECSP056089A/es unknown
- 2005-10-07 NI NI200500175A patent/NI200500175A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EG24122A (en) | 2008-07-06 |
| CN1771230A (zh) | 2006-05-10 |
| MXPA05010685A (es) | 2005-12-12 |
| BRPI0409134A (pt) | 2006-03-28 |
| US20040204587A1 (en) | 2004-10-14 |
| KR20050120788A (ko) | 2005-12-23 |
| CA2521294A1 (en) | 2004-10-28 |
| AU2004230864A1 (en) | 2004-10-28 |
| US6933388B2 (en) | 2005-08-23 |
| WO2004092138A1 (en) | 2004-10-28 |
| RU2333909C2 (ru) | 2008-09-20 |
| NO20054375L (no) | 2005-10-12 |
| NI200500175A (es) | 2006-05-04 |
| CL2004000758A1 (es) | 2005-02-04 |
| CR7991A (es) | 2006-05-31 |
| AR043988A1 (es) | 2005-08-17 |
| JP2006522810A (ja) | 2006-10-05 |
| EP1611103A1 (en) | 2006-01-04 |
| UA80607C2 (en) | 2007-10-10 |
| TW200504024A (en) | 2005-02-01 |
| CN100376558C (zh) | 2008-03-26 |
| CO5640089A2 (es) | 2006-05-31 |
| RU2005134653A (ru) | 2006-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123817T1 (el) | Μεθοδος για την παρασκευη ενωσεων που ειναι χρησιμες ως αναστολεις sglt | |
| EA201000113A1 (ru) | Пиразольные соединения | |
| EA202092558A1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА ИНГИБИТОРА c-MET, ЕГО СОЛЕВАЯ ФОРМА И СПОСОБ ИХ ПОЛУЧЕНИЯ | |
| EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| CY1113992T1 (el) | Αναλογα κιναζολινης ως αναστολεις υποδοχεων κινασης της τυροσινης | |
| EA201071264A1 (ru) | Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера | |
| EA200300829A1 (ru) | Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| EA200600621A1 (ru) | Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств | |
| EA200501504A1 (ru) | Лиганды каннабиноидных рецепторов и их применение | |
| EA201171489A1 (ru) | Аминопиримидиновые противораковые соединения | |
| EA201070186A1 (ru) | Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа | |
| EA201000642A1 (ru) | 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы | |
| EA201100517A1 (ru) | Способ получения дабигатрана и его промежуточные соединения | |
| EA200701588A1 (ru) | Способы получения замещённых фенилпиразолмочевин | |
| CY1111733T1 (el) | Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri | |
| EA200301142A1 (ru) | Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| GT200500296A (es) | Sintesis asimetrica de derivados del dehidrobenzofurano | |
| EA200970936A1 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА | |
| EA201891772A1 (ru) | Трифторацетатная соль агониста tlr7 и ее кристаллическая форма b, способы получения и использование | |
| EA200600605A1 (ru) | Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств | |
| CY1115729T1 (el) | Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης | |
| ECSP055693A (es) | Proceso para la síntesis de intermediarios útiles para la síntesis de inhibidores de la tubulina | |
| NI200500175A (es) | Proceso para la sintesis de 3-ciano-6-alcoxi-7-nitro-4-quinolonas | |
| DK1745010T3 (da) | Substituerede cyklohexyl-1,4-diaminderivater |